BioSpace News Archive

Kintara Therapeutics, Inc. today announced that its President and CEO, Robert E. Hoffman will present in the Emerging Growth Conference on Wednesday, August 9, 2023 at 12:00 pm ET.

T2 Biosystems, Inc. today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2).

Inspira™ Technologies OXY B.H.N. Ltd., a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.

AVM Biotechnology has been selected as a 2023-2024 National Cancer Institute showcase company for the SBIR Investor Initiatives.

HeartBeam, Inc. (NASDAQ: BEAT) today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q2 2023 operational and financial results on Tuesday, August 15, 2023 at 8:30 AM ET.

Stealth BioTherapeutics announced that The Michael J. Fox Foundation for Parkinson’s Research awarded a research grant to evaluate Stealth’s mitochondria-targeted molecule, SBT-272, for Parkinson’s disease.

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.

NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the pricing of its underwritten initial public offering of 1,098,667 shares of common stock at an initial public offering price of $6.00 per share.

Mekonos, Inc., a biotech platform company building the future of cell therapies on a chip, today announced the appointment of Benjamin Borgo, MBA, PhD, as chief operating officer.